SB 1047 would create a new section of Missouri insurance law requiring health benefit plans to limit out-of-pocket costs for treatment of advanced stage cancer. The bill defines advanced stage cancer and related insurance terms, then establishes a new named provision, the "Missouri Advanced Stage Cancer Cost Burden Cap." Under the bill, insurers could not impose cost-sharing requirements such as copayments, coinsurance, deductibles, or similar expenses for advanced stage cancer treatment beyond the deductible that already applies to other covered health care services under the plan.
In practical terms, the bill would protect patients with advanced stage cancer from most treatment-related cost sharing, shifting more of the financial burden to insurers and health plans. It would amend Chapter 376, RSMo, by adding section 376.1263 and would apply to health benefit plans as defined in existing Missouri law. The measure is focused specifically on cancer treatment coverage and does not appear to alter broader insurance benefit mandates beyond this cost-sharing limitation.
Impact
The bill would add a new insurance mandate in Missouri law governing health benefit plans, specifically limiting cost-sharing for advanced stage cancer treatment. It would affect insurers, health plans, and policyholders by prohibiting most out-of-pocket charges for covered treatment of advanced stage cancer, while preserving only the deductible otherwise applicable to other health care services. The bill would amend Chapter 376, RSMo, by creating section 376.1263 and would likely increase coverage obligations for insurers and reduce direct treatment costs for affected patients.
Sentiment
Based on the bill text and available context, the measure appears to be framed as a patient-protection and affordability bill, with an emphasis on reducing the financial burden of cancer care. No committee transcripts or recorded votes were provided, so there is no direct evidence of formal support or opposition in the available record. The overall tone of the legislation suggests a sympathetic approach toward patients facing serious illness and high treatment costs.
Contention
The main likely point of contention is the cost impact on insurers and health plans, since the bill would require them to absorb more of the expense of advanced stage cancer treatment by eliminating most cost-sharing. Supporters would likely emphasize access to care and financial relief for patients, while opponents or skeptics may focus on premium increases, actuarial impacts, or the precedent of mandating special treatment for one disease category. Because no hearing testimony or votes are included, the specific positions of legislators, insurers, patient advocates, or employer groups are not documented here.